Trial · NCT01846182
Research Examining Gulf War Illness in Our Nations Service Members
NCT01846182, Phase 2, Terminated, VA Office of Research and Development; results first posted 2021-03-12
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Research Examining Gulf War Illness in Our Nations Service Members. Trials, record NCT01846182. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01846182
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Research Examining Gulf War Illness in Our Nations Service Members
- NCT number
- NCT01846182
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 112 participants, actual
- Lead sponsor
- VA Office of Research and Development
- Conditions
- Gulf War Illness
- Interventions
- Duloxetine, Pregabalin, Placebo
- First posted
- 2013-05-03
- Last updated
- 2021-03-12
- Results first posted
- 2021-03-12
- Limitations and caveats
The study was closed by the sponsor. Recruiting was very difficult and there were multiple irregularities in enrollment, data collection, and study management. The data are unreliable for interpretation.
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Pain by Likert Scale | 120 days | Likert scale of pain rating |
| Secondary | Side Effects | Assessed every 2 weeks | Side effects checklist |
| Other | Multiple and Unreliable | Assessed every 2 weeks up to 34 weeks | Reliability of measurement is highly suspect and data are not suitable for analysis. |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Pain by Likert Scale | 120 days | Data collection was inaccurate and data are considered unreliable for evaluation. | ||
| SECONDARY | Side Effects | Assessed every 2 weeks | Data collection was inaccurate and data are considered unreliable for evaluation. | ||
| OTHER_PRE_SPECIFIED | Multiple and Unreliable | Assessed every 2 weeks up to 34 weeks | Data were inaccurately collected and are considered unreliable for interpretation. |
Source ClinicalTrials.gov
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow9
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Group 1 | 0 | |
| Overall Study | STARTED | Group 2 | 0 | |
| Overall Study | STARTED | Group 3 | 0 | |
| Overall Study | COMPLETED | Group 1 | 0 | |
| Overall Study | COMPLETED | Group 2 | 0 | |
| Overall Study | COMPLETED | Group 3 | 0 | |
| Overall Study | NOT COMPLETED | Group 1 | 0 | |
| Overall Study | NOT COMPLETED | Group 2 | 0 | |
| Overall Study | NOT COMPLETED | Group 3 | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals9
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Group 1 | 0 | 0 |
| Total, all-cause mortality | Group 2 | 0 | 0 |
| Total, all-cause mortality | Group 3 | 0 | 0 |
| Total, other adverse events | Group 1 | 0 | 0 |
| Total, other adverse events | Group 2 | 0 | 0 |
| Total, other adverse events | Group 3 | 0 | 0 |
| Total, serious adverse events | Group 1 | 0 | 0 |
| Total, serious adverse events | Group 2 | 0 | 0 |
| Total, serious adverse events | Group 3 | 0 | 0 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01846182
GET https://conductscience.org/api/trials/v1/NCT01846182/registered